Free Trial
ASX:CYC

Cyclopharm (CYC) Stock Price, News & Analysis

About Cyclopharm Stock (ASX:CYC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10,000 shs
Average Volume
N/A
Market Capitalization
A$219.50 million
P/E Ratio
N/A
Dividend Yield
0.74%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclopharm and its competitors with MarketBeat's FREE daily newsletter.

CYC Stock News Headlines

I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:CYC
CIK
N/A
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-A$9.32 million
Net Margins
-40.69%
Pretax Margin
N/A
Return on Equity
-23.34%
Return on Assets
-15.37%

Debt

Debt-to-Equity Ratio
11.72
Current Ratio
4.38
Quick Ratio
4.68

Sales & Book Value

Annual Sales
A$24.06 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
8.40
Book Value
A$0.50 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
111,140,000
Free Float
N/A
Market Cap
A$219.50 million
Optionable
Not Optionable
Beta
0.70
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:CYC) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners